Henry Hsu

Henry founded Allysta and serves as its CEO and board member. He has extensive experience leading teams in all stages of drug development, from lead identification through Phase 3 NDA submissions, and has worked in multiple therapeutic areas, with a particular interest in ocular and liver diseases. He was a co-founder, CEO, and board member of Altheos, Inc., a private biopharmaceutical company in ophthalmic drug development. He has served as Chief Medical Officer at a number of companies, including Plexxikon, Inc., and was an early executive at CoMentis, and Molecular Therapeutics, where he had a key role in securing more than $250 million in partnerships and financings and lead the introduction of a number of new compounds in multiple INDs and across multiple indications. Previously, Henry lead drug development teams at CoTherix, InterMune, and Chiron. He received his MD from the University of California, San Francisco, and completed fellowship training at Stanford Medical Center in liver disease, where he was a Howard Hughes Physician Research Fellow.